CN116270949A - 一种降低高尿酸的中药组合物及其制备方法 - Google Patents
一种降低高尿酸的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN116270949A CN116270949A CN202310039044.4A CN202310039044A CN116270949A CN 116270949 A CN116270949 A CN 116270949A CN 202310039044 A CN202310039044 A CN 202310039044A CN 116270949 A CN116270949 A CN 116270949A
- Authority
- CN
- China
- Prior art keywords
- powder
- components
- taking
- paste
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 115
- 238000012360 testing method Methods 0.000 claims abstract description 84
- 230000000694 effects Effects 0.000 claims abstract description 63
- 239000006187 pill Substances 0.000 claims abstract description 41
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 30
- 235000014347 soups Nutrition 0.000 claims abstract description 26
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 24
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 24
- 241000222640 Polyporus Species 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 241000736199 Paeonia Species 0.000 claims abstract description 15
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 244000171085 Polyporus umbellatus Species 0.000 claims abstract description 13
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims abstract description 13
- 241000737241 Cocos Species 0.000 claims abstract description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 9
- 241000092668 Artemisia capillaris Species 0.000 claims abstract description 7
- 235000008658 Artemisia capillaris Nutrition 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 77
- 239000007787 solid Substances 0.000 claims description 42
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000012071 phase Substances 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 31
- 239000012065 filter cake Substances 0.000 claims description 27
- 238000002390 rotary evaporation Methods 0.000 claims description 27
- 239000012074 organic phase Substances 0.000 claims description 26
- 239000008346 aqueous phase Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 19
- 239000003480 eluent Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 244000144730 Amygdalus persica Species 0.000 claims description 13
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 13
- 239000004863 Frankincense Substances 0.000 claims description 13
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 13
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 12
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 12
- 240000001851 Artemisia dracunculus Species 0.000 claims description 12
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 12
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 12
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 12
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 12
- 240000007551 Boswellia serrata Species 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 239000001138 artemisia absinthium Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 12
- 241000545744 Hirudinea Species 0.000 claims description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 241000173529 Aconitum napellus Species 0.000 claims description 10
- 241000213006 Angelica dahurica Species 0.000 claims description 10
- 241000132012 Atractylodes Species 0.000 claims description 10
- 240000007311 Commiphora myrrha Species 0.000 claims description 10
- 241000218176 Corydalis Species 0.000 claims description 10
- 241000218671 Ephedra Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 10
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 10
- 244000236658 Paeonia lactiflora Species 0.000 claims description 10
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 10
- 244000273928 Zingiber officinale Species 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- 235000008397 ginger Nutrition 0.000 claims description 10
- 244000077995 Coix lacryma jobi Species 0.000 claims description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 9
- 239000005977 Ethylene Substances 0.000 claims description 9
- 244000111489 Gardenia augusta Species 0.000 claims description 9
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 9
- 244000131316 Panax pseudoginseng Species 0.000 claims description 9
- 241001180876 Saposhnikovia Species 0.000 claims description 9
- 229940023019 aconite Drugs 0.000 claims description 9
- 108010052008 colla corii asini Proteins 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 239000002344 surface layer Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 229940045860 white wax Drugs 0.000 claims description 3
- 229910010293 ceramic material Inorganic materials 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 238000009775 high-speed stirring Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 9
- 229940116269 uric acid Drugs 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 8
- 210000001835 viscera Anatomy 0.000 abstract description 5
- 239000002674 ointment Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 52
- 239000008280 blood Substances 0.000 description 52
- 208000002193 Pain Diseases 0.000 description 26
- 230000036407 pain Effects 0.000 description 24
- 230000001737 promoting effect Effects 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 230000008961 swelling Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 208000004880 Polyuria Diseases 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000035619 diuresis Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 9
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 8
- 229960004134 propofol Drugs 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 239000002893 slag Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 231100000956 nontoxicity Toxicity 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 241000723422 Catalpa Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 240000009023 Myrrhis odorata Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000745988 Phyllostachys Species 0.000 description 3
- 240000005049 Prunus salicina Species 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000005976 liver dysfunction Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000009137 wuling Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000830536 Tripterygium wilfordii Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015398 thunder god vine Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000008843 wulingsan Substances 0.000 description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 241001444063 Aronia Species 0.000 description 1
- 235000007425 Aronia melanocarpa Nutrition 0.000 description 1
- 240000005662 Aronia melanocarpa Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021129 Postpartum disease Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000029785 Puerperal disease Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042345 Subcutaneous haematoma Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降低高尿酸的中药组合物,包括桂枝芍药知母汤组分、五苓散组分、猪苓汤组分、茵陈蒿汤组分及辅料组分,其制备方法包括:S1、提取并分离桂枝芍药知母汤组分,得靶向分离后的甲膏;S2、提取并分离五苓散组分,得靶向分离后的乙膏;S3、提取并分离猪苓汤组分、茵陈蒿汤组分及辅料组分,得靶向分离后的丙粉I和丙粉II;S4、制取成品药丸。本发明的成品药丸服用量大为减少,吞服便利;更为重要的是,本发明属于对中药组分的靶向提纯,提取率更高,充分结合古配方经验和现有中药材微量成分靶向提纯技术,通过科学合理的交叉试验摒弃药材中对高尿酸无效的组分,降低对内脏的负担,且疗程短,见效快,安全可靠。
Description
技术领域
本发明涉及中成药炮制技术领域,尤其涉及一种降低高尿酸的中药组合物及其制备方法。
背景技术
高尿酸是嘌呤因代谢发生紊乱,致使血液中尿酸增多而引起的一种代谢性疾病。高尿酸血症如未得到有效控制,可能会发展为痛风,继而出现反复发作的痛风性关节炎、间质性肾炎和痛风石形成,严重者伴关节畸形或尿酸性尿路结石。
西药别嘌呤醇常用来干预人体排放尿酸的水平,但由于高尿酸常引起多种并发症,而且对于高血脂高胆固醇的患者而言,仅仅降低尿酸水平是远远不够的,因此常又加一些中药制剂配合治疗。如钟云良等采用黄芪合四妙散的方剂治疗高尿酸血症,如朱章帅等采用桂枝芍药知母汤合二陈汤合四妙散加减的方剂治疗痛风等等,说明中成药在治疗高尿酸的同时具有治理湿热、消炎抗菌、降低尿蛋白、调理身体以及增强胆固醇和脂代谢上有效果,且中成药的副作用较小,可降低对肝肾的负担。
但现有中成药存在成分较为复杂、炮制工艺不一及服用量较大等问题,尤其是古配方药剂成分多且尚无统一标准,各医师在配伍时存在较大差异,疗效慢、康复周期长甚至存在无效治疗的风险。因此本发明结合现代医药提纯技术及古配方的精妙配伍方法,试图实现中成药服用减量化、治疗高效化以及治理精确化。
发明内容
本发明的目的是为了解决现有技术中存在的缺点,而提出的一种降低高尿酸的中药组合物及其制备方法。
为了实现上述目的,本发明采用了如下技术方案:
一种降低高尿酸的中药组合物,包括以下标准克用量的组分:
桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;
五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;
猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;
茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;
辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;
实际配伍时,以上中药成分的实际克用量为标准克用量的80%~120%。
经过总结前人的模型实验及临床实验的调查发现,桂枝芍药知母汤治疗痛风具有多靶点、多通路特点,从抗炎、调节机体免疫、保护细胞、抑制骨破坏、降低血清尿酸、镇痛等多个机制发挥治疗作用。
五苓散能降低黄嘌呤氧化酶活性、使尿酸生成减少,改善尿酸代谢、能够有效改善患者的肝功能、具保护肝细胞完整性,促进肝细胞的再生和修复、有降血脂、能改善肝脏的脂肪代谢的功能,猪苓汤能促进尿酸代谢从而减轻肾损害,茵陈蒿汤有降低糖化血红蛋白、甘油三酯、胆固醇、高密度脂蛋白、低密度脂蛋白、谷丙转氨酶、谷草转氨酶、血尿酸水平的作用,对非酒精性脂肪肝患者临床效果较好,可改善患者肝功能和减轻患者主要症状,用药安全性良好。乳香有镇痛、消炎的作用,并能加速炎症渗出排泄,没药其含油脂部分具有降脂、防止动脉内膜粥样硬化板块形成的作用,水蛭能降血脂,消退动脉粥样硬化斑块,对皮下血肿有明显抑制作用,可降低血清尿素氮、肌酐水平;地龙中蚯蚓解热碱有良好的解热作用,还有抗菌、利尿的作用;桃仁能改善血流动力学状况,提取物能改善动物肝脏表面循环,其水煎剂及提取物有镇痛、抗炎、抗菌、抗过敏的作用;延胡索有明显镇痛、镇静的作用;白芷具有解热、抗炎、镇痛、解痉的作用。薏苡仁具有降血糖、解热镇静、镇痛的作用。以上为该处方的中药药理研究,证明其对于高尿酸血症、或者因此引起的局部疼痛症状,确有效果。
从中国传统医学角度,上述方药的中医作用有,桂枝芍药知母汤出自东汉·张仲景《金匮要略·中风历节病脉证并治第五》,其论述如下“诸肢节疼痛,身体尫羸,脚肿如脱,头眩短气,温温欲吐,桂枝芍药知母汤主之。”此久痹而出方也,乃脾胃肝肾俱虚,足三阴表里皆痹,难拘一经主治,故用桂枝、芍药、甘、术调和营卫,充益五脏之元;麻黄、防风、生姜开腠行痹而驱风外出;知母保肺清金以使治节;经谓风、寒、湿三气合而为痹,以附子行阳燥湿除寒为佐也。其主要功能是祛风除湿、清阳散寒、清热。方中麻黄、桂枝祛风通阳,白术、防风祛风除湿,芍药、知母养阴清热;附子温经散寒止痛;生姜、甘草和胃调中,全方合用有通阳行痹,散风化湿之效。猪苓汤出自东汉·张仲景《伤寒论·辨阳明病脉证并治》:"若脉浮,发热,渴欲饮水,小便不利者,猪苓汤主之。"《伤寒论·辨少阴病脉证并治》:"少阴病,下利六七日,咳而呕渴,心烦不得眠者,猪苓汤主之。"方中以猪苓为君,取其归肾、膀胱经,专以淡渗利水。臣以泽泻、茯苓之甘淡,益猪苓利水渗湿之力,且泽泻性寒兼可泄热,茯苓尚可健脾以助运湿。佐入滑石之甘寒,利水、清热两彰其功;阿胶滋阴润燥,既益已伤之阴,又防诸药渗利重伤阴血。五药合方,利水渗湿为主,清热养阴为辅,体现了利水而不伤阴、滋阴而不碍湿的配伍特点。水湿去,邪热清,阴津复,诸症自除。
五苓散出自东汉张仲景的《伤寒论》书中曰:“太阳病,发汗后,大汗出,胃中干,烦躁不得眠,欲得饮水者,少少与饮之,令胃气和则愈。若脉浮,小便不利,微热,消渴者,五苓散主之。发汗已,脉浮数,烦渴者,五苓散主之。中风发热,六七日不解而烦,有表里证,渴欲饮水,水入则吐者,名曰水逆,五苓散主之。”重用泽泻为君,以其甘淡,直达肾与膀胱,利水渗湿。臣以茯苓、猪苓之淡渗,增强其利水渗湿之力。佐以白术、茯苓健脾以运化水湿。《素问·灵兰秘典论》谓:“膀胱者,州都之官,津液藏焉,气化则能出矣”,膀胱的气化有赖于阳气的蒸腾,故方中又佐以桂枝温阳化气以助利水,解表散邪以祛表邪,《伤寒论》示人服后当饮暖水,以助发汗,使表邪从汗而解。诸药相伍,甘淡渗利为主,佐以温阳化气,使水湿之邪从小便而去。
茵陈蒿汤出自东汉张仲景的《伤寒论·辨阳明病脉证并治》:"伤寒七八日,身黄如橘子色,小便不利,腹微满者,茵陈蒿汤主之。"《金匮要略·黄疸病脉证并治》:"谷疸之为病,寒热不食,食即头眩,心胸不安,久久发黄为谷疸,茵陈蒿汤主之。"方中重用茵陈为君药,本品苦泄下降,善能清热利湿,臣以栀子清热降火,通利三焦,助茵陈引湿热从小便而去。佐以大黄泻热逐瘀,通利大便,导瘀热从大便而下。
乳香辛苦,温。入心、肝、脾经。具有调气活血,定痛,追毒的作用。古人相关论述如下《别录》:疗风水毒肿,去恶气。疗风瘾疹痒毒。《珍珠囊》:定诸经之痛。《纲目》:消痈疽诸毒,托里护心,活血定痛,伸筋,治妇人难产,折伤。
没药苦,辛,平。具有活血止痛、消肿生肌等功效。古人相关论述有李中梓·《雷公炮制药性解》:味苦、辛,性平,无毒,入十二经。主破癥结宿血,止痛,疗金疮、杖疮、痔疮,诸恶肿毒,跌打损伤,目中翳晕,历节诸风,骨节疼痛,制同乳香。没药与乳香同功,大抵血滞则气壅淤,气壅淤则经络满急,故痛且肿,得没药以宣通气血,宜其治也。黄元御·《玉楸药解》:味苦,气平,入足厥阴肝经。破血止痛,消肿生肌。没药破血行瘀,化老血宿癥,治痈疽痔漏、金疮杖疮、跌扑损伤、一切血瘀肿痛。疗经期产后、心腹疼痛诸证。制同乳香。
水蛭,咸苦,平。入肝、膀胱经。古人论述《本经》:“主逐恶血、瘀血、月闭,破血瘕积聚,无子,利水道。”《本草拾遗》:“人患赤白游疹及痈肿毒肿,取十余枚令啖病处,取皮皱肉白,无不差也。”《本草衍义》:“治伤折。”
地龙,咸,寒。归肝、脾、膀胱经。具有清热息风,平喘,通络,利尿的作用,古人论述如下:《神农本草经》味咸,寒。主蛇瘕,去三虫,伏尸,鬼疰,蛊毒,杀长虫,仍自化作水。陶弘景·《本草经集注》,味咸,寒、大寒,无毒。主治蛇瘕,去三虫,伏尸,鬼疰,蛊毒,杀长虫,仍自化作水。
桃仁,苦,平。归心、肝、肺、大肠经,具有活血祛瘀,润肠通便的作用。古人论述如下:《神农本草经》苦,平。主瘀血,血闭,癥瘕,邪气。杀小虫。陶弘景·《本草经集注》,味苦、甘,平,无毒。主治瘀血,血闭,癥瘕,邪气。杀小虫。主咳逆上气,消心下坚,除卒暴击血,破癥瘕,通月水,止痛。李中梓·《雷公炮制药性解》:味苦甘,性平,无毒。入肝、大肠二经,主瘀血血闭,癥瘕鬼邪,血燥便结,杀三虫,止心痛。沸汤泡去皮尖,炒用。桃仁行血,宜入肝经,性润,宜入大肠。叶天士·《本草经解》:气平,味苦甘,无毒,主瘀血,血闭癥瘕邪气,杀小虫,(双仁者大毒)桃仁气平,禀天秋收之金气,入手太阴肺经,味苦甘无毒,得地中南火土之味,入手少阴心经、足太阴脾经,气味降多于升,阴也,心主血,脾统血,血者阴也,有形者也,周流乎一身,灌溉乎五脏者也,一有凝滞,非瘀即闭矣,至有形可征即成症,假物成形则成瘕,盖皆心脾不运故也,桃仁甘以和血,苦以散结,则瘀者化,闭者通,而积者消矣,桃为五木之精,能镇辟不祥,所以主邪气,禀火之苦味,所以杀小虫也。黄元御·《长沙药解》:味甘、苦、辛,入足厥阴肝经。通经而行瘀涩,破血而化癥瘕。
三七,甘、微苦,温。归肝、胃经。具有化瘀止血,活血定痛的作用。黄元御·《玉楸药解》论述:味甘,微苦,入足厥阴肝经。和营止血,通脉行瘀。三七行瘀血而敛新血,凡产后、经期、跌打、痈肿,一切瘀血皆破,凡吐衄、崩漏、刀伤、箭射,一切新血皆止,血产之上药也。
延胡索,辛、苦,温。归心、肝、脾经。具有活血,行气,止痛的作用。古人论述,李中梓·《雷公炮制药性解》:味苦、辛,性温,无毒,入心、肺、脾、胃四经。活精血,疗产后之疾,调月水,主胎前之证。一切因血作痛之证并治,酒炒行血,醋炒止血,生用破血,炒用调血。玄胡索可升可降,为阴中之阳,故能行上下四经,此理血之剂也。叶天士·《本草经解》:气温,味辛,无毒。主破血,妇人月经不调,腹中结块,崩中淋露,产后诸血症,血晕,暴血冲上。因损下血。
白芷,辛,温。归肺、胃经。具有解表,祛风燥湿,消肿排脓,止痛的作用。古人论述如下:《神农本草经》:味辛,温。主女人漏下赤白,血闭,阴肿,寒热,风头,侵目,泪出,长肌肤、润泽,可作面脂。陶弘景·《本草经集注》:味辛,温,无毒。主治女人漏下赤白,血闭,阴肿,寒热,风头侵目泪出,长肌肤润泽,可作面脂。治风邪,久渴,吐呕,两胁满,风痛,头眩,目痒,可作膏药面脂,润颜色。李中梓·《雷公炮制药性解》:味辛,性温,无毒,入肺、脾、胃三经。去头面皮肤之风,除肌肉燥痒之痹,止阳明头痛之邪,为肺部引经之剂。主排脓托疮,生肌长肉,通经利窍,止漏除崩,明目散风,驱寒燥湿。白芷味辛,为肺所喜,而温燥为脾胃所喜,宜其入矣。叶天士·《本草经解》:气温,味辛,无毒。主女人漏下赤白,血闭,阴肿寒热,头风侵目泪出,长肌肉。润泽颜色,可作面脂。
薏苡仁,甘、淡,微寒。归脾、胃、肺经。利水渗湿,健脾,除痹,清热排脓。古人论述:《神农本草经》:味甘,微寒。主筋急,拘挛不可屈伸,风湿痹,下气。久服轻身益气。其根下三虫。陶弘景·《本草经集注》:味甘,微寒,无毒。主治筋急拘挛,不可屈伸,风湿痹,下气。除筋骨邪气不仁,利肠胃,消水肿,令人能食。久服轻身益气。其根下三虫。整体来看,上述药物的配伍有养元清浊,活血化瘀的作用,用于痰湿内阻,瘀血阻滞之痛风、肥胖、浮肿、腰酸,关节疼痛等症。
可根据患者自身健康状态实现针对性配伍,如患者痛风严重且关节炎等炎症并发则可增加桂枝芍药知母汤组分的克用量,如患者肝功能异常可增加五苓散组分的克用量以保肝,如患者有肾炎可增加猪苓汤组分的克用量以护肾,如患者有高血脂则可增加辅料组分的用量,等等诸如此类。
药方炮制分析:
桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;
猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;
茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;
根据古配方的配伍,各汤剂原方为加水煎制成汤,剂量较大且渣料则完全废弃,其中有效成分可能有较大损失,根据对前人所做相关中药组分的提纯工作,渣料中含有大量膳食纤维、花青素以及微量元素等等,有利于保护有机成分活性。因此本发明采用深度提取方式并将提取后的渣料留存,以作为药丸增稠物使用。
五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;
辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;
根据古配方的配伍,五苓散及辅料组分直接碾碎或糅制成散,冲水而服,该药剂入腹后缓慢释放有效组分,容易在被人体吸收之前就排泄出去,从而影响疗效。因此本发明采用深度提取方式并将提取后的渣料留存,以作为药丸增稠物使用,并根据现有提取技术,该各组分具有抗氧化性,进一步考察各渣料对有效成分的抗氧化保护作用。
在药方调研和分析后,本发明提出一种降低高尿酸的中药组合物的制备方法,包括以下步骤:
1)取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,置于索氏提取器中,8085℃下提取2 3h,保持液温为75±3℃浸泡56h;加入正丁醇1.5L萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,将下层水相连带沉淀物在120℃油浴加热蒸发,得膏状物I,共1419.4g,标记为甲A组分;吸取中层绒状物,蒸发得膏状物II,共138.5g,标记为甲B组分;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,经过氯仿和甲醇体积比为5:1为展开剂分析,以极性增大的顺序,依次分离为甲C、甲D和甲E三个组分;
2)取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗23次,再经由乙酸乙酯清洗23次,得到湿滤饼I,共588.1g,标记为乙A组分;得到滤液I,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物III,共35.3g,标记为乙B组分;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为2:1为展开剂分析,以极性增大的顺序,依次分离为乙C、乙D和乙E三个组分;
3)取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗23次,再经由乙酸乙酯清洗23次,得到湿滤饼II,共1165.9g,标记为丙A组分;得到滤液II,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物IV,共127.4g,标记为丙B组分;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1为展开剂分析,以极性增大的顺序,依次分离为丙C、丙D和丙E三个组分;
4)将甲A、甲B、甲C、甲D和甲E列为甲组,将乙A、乙B、乙C、乙D和乙E列为乙组,将丙A、丙B、丙C、丙D和丙E列为丙组,甲乙丙三组进行混合后,进行交叉试验,以传统炮制法作为对比试验,以甲乙丙三组混合全成分为标准试验,依次试验甲乙丙三组中A E各组分的治疗有效性,最终得出结论:甲组中甲B和甲D为有效成分,甲C有辅助疗效的作用;乙组中乙B和乙E为有效成分,乙D有辅助疗效的作用;丙组中丙C和丙D为有效成分,丙A有辅助疗效的作用;
5)取甲B、甲C和甲D全部,取乙B、乙D和乙E全部,取丙C和丙D全部,取丙A部分,控制含水量为10±2%,制成药丸。
优选地,步骤2)和3)中,乙酸乙酯占滤液体积总量的40 60%。
在前述的试验基础上,本发明还得出一种更优的制备方法,包括以下步骤:
S1、取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,置于索氏提取器中,80 85℃下提取23h,保持液温为75±3℃浸泡56h;加入正丁醇500ml萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,弃置水相及沉淀物,吸取中层绒状物备用;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,以氯仿和甲醇体积比为2:1为洗脱剂,洗脱去多余部分,余下部分与中层绒状物混合50℃旋蒸成膏,共158.6g,标记为甲膏;
S2、取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗23次,再经由乙酸乙酯清洗23次,弃置滤饼,得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相备用;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为1:1为洗脱剂进行洗脱,弃置其余部分,得到的洗脱液与下层水相混合后80℃旋蒸成膏,共50.7g,标记为乙膏;
S3、取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗23次,再经由乙酸乙酯清洗23次,得到的湿滤饼经真空干燥得到米白色粉末,共929.6g,标记为丙粉I备用;得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,弃置下层水相;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1的洗脱剂进行洗脱,洗脱去多余部分,余下部分则以乙酸乙酯洗脱,最终得到的洗脱液在70℃旋蒸,得白色粉末,共15.4g,标记为丙粉II备用;
S4、取158.6g甲膏、50.7g乙膏、15.4g丙粉II和7091g丙粉I,鞣制成团,鞣制成团,再压制成丸,丸剂加入到剩余丙粉I中,振动筛除去多余丙粉I,表层粘附有丙粉I的丸剂,挂糖衣制成蜜丸,将蜜丸与直径约0.5cm的玻璃珠以及小块虫白蜡混合,投入到磨光机中进行磨光,得到表面光滑且呈棕褐色的浓缩水丸成品,每颗重量为0.2~0.8g,300g的原料约可制成373~1500颗,日服用量为7.2~20g,相比传统配方制剂几百乃至几千毫升的日饮用量,本发明的成品药丸服用量大为减少,吞服便利;更为重要的是,本发明属于对中药组分的靶向提纯,提取率更高,充分结合古配方经验和现有中药材微量成分靶向提纯技术,通过科学合理的交叉试验摒弃药材中对高尿酸无效的组分,降低对内脏的负担,且疗程短,见效快,安全可靠。
优选地,所述溶剂I中乙醇:水的体积比为23:1,传统炮制只用水煎制药汤,对有机成分,尤其对治疗高尿酸有效的类黄酮物质和甾类物质等提取效率有限。
优选地,所述中层绒状物为带有透光效应的胶体体系,其颗粒较小且悬浮于水面且不溶于有机相,故形成一层厚度约为3cm的浑浊液状。
优选地,所述溶剂II为重量浓度为30%的盐酸水溶液,pH为1.1
1.3,模拟胃液酸度,对药丸进行分解提纯。
优选地,所述破壁机的高速搅拌的转速大于30000r/min,且破壁机内壁和搅拌桨均采用耐高温陶瓷材质。
与现有技术相比,本发明的有益效果是:
1.相比传统配方制剂几百毫升的日饮用量,本发明的成品药丸服用量大为减少,吞服便利;
2.更为重要的是,本发明属于对中药组分的靶向提纯,提取率更高,充分结合古配方经验和现有中药材微量成分靶向提纯技术,通过科学合理的交叉试验摒弃药材中对高尿酸无效的组分,降低对内脏的负担,且疗程短,见效快,安全可靠。
3.综上所述该方来治疗人们之常见病、多发病的高脂血症(总胆固醇、甘油三酯、低密度脂蛋白)、高尿酸血症、肝功能异常等疾病有着十分确切的作用,我们经过临床应用,其整体有效率在90%以上,并利用现代化植物微量成分靶向提纯技术将上述中药有效成分提纯,再应用粘合剂将上述药物制成易于口服、易于保存的中药丸剂。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。
一、药方有效成分的交叉试验:
一种降低高尿酸的中药组合物的制备方法,包括以下步骤:
1)取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,溶剂I取乙醇:水的体积比为2.5:1,置于索氏提取器中,82℃下提取2.5h,保持液温为76℃浸泡5.5h;加入正丁醇1.5L萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,将下层水相连带沉淀物在120℃油浴加热蒸发,得膏状物I,共1419.4g,标记为甲A组分;吸取中层绒状物,蒸发得膏状物II,共138.5g,标记为甲B组分;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,经过氯仿和甲醇体积比为5:1为展开剂分析,以极性增大的顺序,依次分离为甲C、甲D和甲E三个组分;
2)取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2次,再经由乙酸乙酯清洗3次,得到湿滤饼I,共588.1g,标记为乙A组分;得到滤液I,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物III,共35.3g,标记为乙B组分;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为2:1为展开剂分析,以极性增大的顺序,依次分离为乙C、乙D和乙E三个组分;
3)取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗3次,再经由乙酸乙酯清洗2次,得到湿滤饼II,共1165.9g,标记为丙A组分;得到滤液II,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物IV,共127.4g,标记为丙B组分;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1为展开剂分析,以极性增大的顺序,依次分离为丙C、丙D和丙E三个组分;
4)将甲A、甲B、甲C、甲D和甲E列为甲组,将乙A、乙B、乙C、乙D和乙E列为乙组,将丙A、丙B、丙C、丙D和丙E列为丙组,甲乙丙三组进行混合后,进行交叉试验,以传统炮制法(即先熬制桂枝芍药知母汤、猪苓汤和茵陈蒿汤,再依次加入五苓散及辅料组分,搅拌后饮服)作为对比试验,以甲乙丙三组混合全成分为标准试验,依次试验甲乙丙三组中AE各组分的治疗有效性(包括疗效、疗程)。
交叉试验数据如下:
尿酸盐沉积的小鼠模型的构建:
1、建模采用中国发明专利ZL201610796365.9(一种利用长期高尿酸血症诱导小鼠痛风模型的方法)提供的造模方法。具体方法为将昆明种小鼠用高脂饲料进行喂养,每天腹腔注射200μL浓度为40mg/ml的氧嗪酸钾,每隔2天,后肢脚掌注射20μL浓度为1%的冰醋酸。在上述条件下持续操作4个月左右,即得。
建模后测量了所有小鼠模型的物理性指标,本发明为了验证各组分的有效性,故仅检测各小鼠脚掌肿胀度,以初始肿胀度为1(测试肿胀最宽处的宽度),后续用药后如有降低应小于1。
2、实验如采用列举法逐个验证各组分的有效性,则需要共15组实验,但考虑中药组分之间的拮抗性或协同增效作用,如此实验有可能不准确,故重新设计正交试验,利用排除法:
1)排除试验一:标准试验:包括甲AE、乙AE和丙AE,搓揉成点粒大小,投喂给小鼠吞服(人体60kg标准重量日服用量为10g,小鼠按体重比例用量,如小白鼠100g则需日服16.67mg),疗程为1个月,测试脚掌肿胀度变化;
试验1:不用甲A、乙C和丙E;
试验2:不用甲B、乙D和丙A;
试验3:不用甲C、乙E和丙B;
试验4:不用甲D、乙A和丙C;
试验5:不用甲E、乙B和丙D;
表1.本发明配方无效组分排除试验一
疗效:试验1>试验3>试验4≈试验5>试验2(≈表明二者相差不超过5%)
排除结论:
①通过试验1疗效基本无影响,表明甲A、乙C和丙E为无效组分,试验有巧合;
②试验3疗效次之,表明可能只有一种有效组分;
③试验4和试验5的疗效再次之,表明其中有重要的有效成分;
④试验2疗效最差,表明该三种组分有可能均为有效成分。
2)排除试验二:故将试验35各排除组分打乱,设计以下试验:
试验6:不用甲C、乙A和丙D,疗效≈试验3,乙A与乙E或丙B与丙D两组中,至少有一种药是无效成分,有一种则是有效成分,之中同之;
设置试验7:不用乙A;
试验8:不用乙E;
疗效:标准试验≈试验7>>试验8(>>代表二者数据相差30%以上),表明乙A为无效成分,乙E为有效成分;
设置试验9:不用丙B;
试验10:不用丙D;
疗效:标准试验≈试验9>>试验10,表明丙B为无效成分,丙D为有效成分;
设置试验11:不用甲C,疗效:标准试验>试验11>试验3,表明甲C为有效成分,疗效降低较少,说明甲C可能起辅助治疗作用。
表2.本发明配方无效组分排除试验二
3)排除试验三:
设置试验12:不用甲D;
试验13:不用甲E;
试验14:不用乙B;
试验15:不用丙C;
疗效:标准试验≈试验13>>试验12≈试验14≈试验15,说明甲D、乙B和丙C均为不可或缺的主要成分,前面已推断甲C为辅助治疗作用,但考虑分离不便,故全取甲C组分;
再设置试验16:不用甲B;疗效≈试验12,推断甲B也为主要成分。
设置试验17:不用乙D;疗效:标准试验>试验17>试验8,乙E为主要成分,乙D为辅助治疗作用。
再设置试验18:不用丙A;疗效:标准试验>试验18>试验10,推断丙D也为主要成分,丙A为辅助治疗作用。
表3.本发明配方无效组分排除试验三
4)至此,得出配方中各组中的有效性如下表4:
表4.本发明配方中各组分的有效性试验结果
5)考虑到丙A为滤渣制品,故试验其用量大小对疗效的影响;
设置试验19:与标准试验相比其余不变,丙A由1165.9g改为35g;
试验20:与试验19相比其余不变,丙A为55g;
试验21:与试验19相比其余不变,丙A为75g;
试验22:与试验19相比其余不变,丙A为100g;
试验23:与试验19相比其余不变,丙A为120g;
试验24:与试验19相比其余不变,丙A为140g;
表5.本发明中丙A的用量对疗效影响
随着丙A用量的增加,疗效缓慢增加后基本持平,表明最佳用量为丙A用量最佳为100g,可最大程度减少服用量。
6)最终得出结论:甲组中甲B和甲D为有效成分,甲C有辅助疗效的作用;乙组中乙B和乙E为有效成分,乙D有辅助疗效的作用;丙组中丙C和丙D为有效成分,丙A有辅助疗效的作用;故最终配方取甲B、甲C和甲D全部,取乙B、乙D和乙E全部,取丙C和丙D全部,取丙A部分,以控制后续制丸的湿度;
二、优化实验设计:
实施例1:
万益养元清浊丸的制备方法,包括以下步骤:
S1、取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,溶剂I取乙醇:水的体积比为2.5:1,置于索氏提取器中,82℃下提取2.5h,保持液温为76℃浸泡5.5h;加入正丁醇1.5L萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,弃置水相及沉淀物,吸取中层绒状物备用;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,以氯仿和甲醇体积比为2:1为洗脱剂,洗脱去多余部分,余下部分与中层绒状物混合50℃旋蒸成膏,共158.6g,标记为甲膏;
S2、取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2次,再经由乙酸乙酯清洗3次,弃置滤饼,得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相备用;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为1:1为洗脱剂进行洗脱,弃置其余部分,得到的洗脱液与下层水相混合后80℃旋蒸成膏,共50.7g,标记为乙膏;
S3、取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗3次,再经由乙酸乙酯清洗2次,得到的湿滤饼经真空干燥得到米白色粉末,共929.6g,标记为丙粉I备用;得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,弃置下层水相;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1的洗脱剂进行洗脱,洗脱去多余部分,余下部分则以乙酸乙酯洗脱,最终得到的洗脱液在70℃旋蒸,得白色粉末,共15.4g,标记为丙粉II备用;
S4、取158.6g甲膏、50.7g乙膏、15.4g丙粉II和78g丙粉I,鞣制成团,鞣制成团,再压制成丸,丸剂加入到剩余丙粉I中,振动筛除去多余丙粉I,表层粘附有丙粉I的丸剂,挂糖衣制成蜜丸,将蜜丸与直径约0.5cm的玻璃珠以及小块虫白蜡混合,投入到磨光机中进行磨光,得到表面光滑且呈棕褐色的浓缩水丸成品。
成品药丸命名为“万益养元清浊丸”,每颗重量为0.2~0.8g,300g的原料约可制成373~1500颗,日服用量为7.2~20g,相比传统配方制剂几百乃至几千毫升的日饮用量,本发明的成品药丸服用量大为减少,吞服便利;更为重要的是,本发明属于对中药组分的靶向提纯,提取率更高,充分结合古配方经验和现有中药材微量成分靶向提纯技术,通过科学合理的交叉试验摒弃药材中对高尿酸无效的组分,降低对内脏的负担,且疗程短,见效快,安全可靠。
本品用于多发病的高脂血症(总胆固醇、甘油三酯、低密度脂蛋白)、高尿酸血症、肝功能异常。进行患者治疗,结果如下表6:
表6.万益养元清浊丸治疗案例
从临床试验,本方不仅可以用来降低高尿酸血症患者的高尿酸,对高尿酸并发产生高脂血症(总胆固醇、甘油三酯、低密度脂蛋白)、肝功能异常等疾病有着十分确切的作用,我们经过临床应用,其整体有效率在90%以上,并利用现代化植物微量成分靶向提纯技术将上述中药有效成分提纯,再应用粘合剂将上述药物制成易于口服、易于保存的中药丸剂。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (8)
1.一种降低高尿酸的中药组合物,其特征在于,包括以下标准克用量的组分:
桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;
五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;
猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;
茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;
辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;
实际配伍时,以上中药成分的实际克用量为标准克用量的80%~120%。
2.一种降低高尿酸的中药组合物的制备方法,其特征在于,包括以下步骤:
取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,置于索氏提取器中,80~85℃下提取2~3h,保持液温为75±3℃浸泡5~6h;加入正丁醇1.5L萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,将下层水相连带沉淀物在120℃油浴加热蒸发,得膏状物I,共1419.4g,标记为甲A组分;吸取中层绒状物,蒸发得膏状物II,共138.5g,标记为甲B组分;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,经过氯仿和甲醇体积比为5:1为展开剂分析,以极性增大的顺序,依次分离为甲C、甲D和甲E三个组分;
取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2~3次,再经由乙酸乙酯清洗2~3次,得到湿滤饼I,共588.1g,标记为乙A组分;得到滤液I,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物III,共35.3g,标记为乙B组分;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为2:1为展开剂分析,以极性增大的顺序,依次分离为乙C、乙D和乙E三个组分;
取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2~3次,再经由乙酸乙酯清洗2~3次,得到湿滤饼II,共1165.9g,标记为丙A组分;得到滤液II,在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相经90℃旋蒸,得到膏状物IV,共127.4g,标记为丙B组分;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1为展开剂分析,以极性增大的顺序,依次分离为丙C、丙D和丙E三个组分;
将甲A、甲B、甲C、甲D和甲E列为甲组,将乙A、乙B、乙C、乙D和乙E列为乙组,将丙A、丙B、丙C、丙D和丙E列为丙组,甲乙丙三组进行混合后,进行交叉试验,以传统炮制法作为对比试验,以甲乙丙三组混合全成分为标准试验,依次试验甲乙丙三组中A~E各组分的治疗有效性,最终得出结论:甲组中甲B和甲D为有效成分,甲C有辅助疗效的作用;乙组中乙B和乙E为有效成分,乙D有辅助疗效的作用;丙组中丙C和丙D为有效成分,丙A有辅助疗效的作用;
取甲B、甲C和甲D全部,取乙B、乙D和乙E全部,取丙C和丙D全部,取丙A部分,控制含水量为10±2%,制成药丸。
3.根据权利要求2所述的一种降低高尿酸的中药组合物的制备方法,其特征在于,所述步骤2)和3)中,乙酸乙酯占滤液体积总量的40~60%。
4.一种降低高尿酸的中药组合物的制备方法,其特征在于,包括以下步骤:
S1、取桂枝芍药知母汤组分:白芍240g,白术180g,桂枝160g,甘草80g,干姜60g,防风160g,麻黄80g,炮附子80g,知母160g;共1200g,干燥至含水量<5%,碾碎成末,加入3L溶剂I中,置于索氏提取器中,80~85℃下提取2~3h,保持液温为75±3℃浸泡5~6h;加入正丁醇500ml萃取,得上层醇相、中层绒状物和下层水相,水相底部有沉淀物,弃置水相及沉淀物,吸取中层绒状物备用;上层醇相110℃旋蒸得固体粉末I,共36.4g,固体粉末I经过甲醇溶解后,以氯仿和甲醇体积比为2:1为洗脱剂,洗脱去多余部分,余下部分与中层绒状物混合50℃旋蒸成膏,共158.6g,标记为甲膏;
S2、取五苓散组分:猪苓50g,泽泻50g,茯苓50g,白术180g,桂枝160g;共490g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,溶剂II取重量浓度为30%的盐酸水溶液,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2~3次,再经由乙酸乙酯清洗2~3次,弃置滤饼,得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,下层水相备用;上层有机相70℃旋蒸,得固体粉末II,共24.1g,固体粉末II经氯仿和乙酸乙酯体积比为1:1为洗脱剂进行洗脱,弃置其余部分,得到的洗脱液与下层水相混合后80℃旋蒸成膏,共50.7g,标记为乙膏;
S3、取猪苓汤组分:猪苓50g,泽泻50g,茯苓50g,阿胶50g,滑石50g;取茵陈蒿汤组分:栀子30g,茵陈90g,大黄30g;取辅料组分:乳香50g,没药50g,水蛭50g,地龙150g,桃仁50g,三七50g,延胡索100g,白芷50g,薏苡仁40g;混合共990g,干燥至含水量<5%,碾碎成末,加入2L溶剂II中,密闭的破壁机中,100℃下高速搅拌提取0.5h,保温静置3h,过滤,将滤饼经过水清洗2~3次,再经由乙酸乙酯清洗2~3次,得到的湿滤饼经真空干燥得到米白色粉末,共929.6g,标记为丙粉I备用;得到的滤液在分液漏斗中充分摇晃后静置分层,得到上层有机相和下层水相,弃置下层水相;上层有机相70℃旋蒸,得固体粉末III,共19.6g,固体粉末III经氯仿和乙酸乙酯体积比为1:1的洗脱剂进行洗脱,洗脱去多余部分,余下部分则以乙酸乙酯洗脱,最终得到的洗脱液在70℃旋蒸,得白色粉末,共15.4g,标记为丙粉II备用;
S4、取158.6g甲膏、50.7g乙膏、15.4g丙粉II和70~91g丙粉I,鞣制成团,再压制成丸,丸剂加入到剩余丙粉I中,振动筛除去多余丙粉I,表层粘附有丙粉I的丸剂,挂糖衣制成蜜丸,将蜜丸与直径约0.5cm的玻璃珠以及小块虫白蜡混合,投入到磨光机中进行磨光,得到表面光滑且呈棕褐色的浓缩水丸成品。
5.根据权利要求2或4所述的一种降低高尿酸的中药组合物的制备方法,其特征在于,所述溶剂I中乙醇:水的体积比为2~3:1。
6.根据权利要求2或4所述的一种降低高尿酸的中药组合物的制备方法,其特征在于,所述中层绒状物为带有透光效应的胶体体系,其颗粒较小且悬浮于水面且不溶于有机相,故形成一层厚度约为3cm的浑浊液状。
7.根据权利要求2或4所述的一种降低高尿酸的中药组合物的制备方法,其特征在于,所述溶剂II为重量浓度为30%的盐酸水溶液,pH为1.1~1.3。
8.根据权利要求2或4所述的一种降低高尿酸的中药组合物的制备方法,其特征在于,所述破壁机的高速搅拌的转速大于30000r/min,且破壁机内壁和搅拌桨均采用耐高温陶瓷材质。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310039044.4A CN116270949A (zh) | 2023-01-13 | 2023-01-13 | 一种降低高尿酸的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310039044.4A CN116270949A (zh) | 2023-01-13 | 2023-01-13 | 一种降低高尿酸的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116270949A true CN116270949A (zh) | 2023-06-23 |
Family
ID=86836715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310039044.4A Pending CN116270949A (zh) | 2023-01-13 | 2023-01-13 | 一种降低高尿酸的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116270949A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105920451A (zh) * | 2016-05-30 | 2016-09-07 | 代军 | 一种治疗痛风的中药配方 |
-
2023
- 2023-01-13 CN CN202310039044.4A patent/CN116270949A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105920451A (zh) * | 2016-05-30 | 2016-09-07 | 代军 | 一种治疗痛风的中药配方 |
Non-Patent Citations (1)
Title |
---|
孙广瀚 等: "中医药治疗痛风性关节炎的研究进展", 《风湿病与关节炎》, vol. 8, no. 8, pages 289 - 293 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103099959B (zh) | 一种治疗溃疡性结肠炎的中药制剂及其制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN102895478B (zh) | 一种温肾助阳的药物组合物及其制备方法 | |
CN103977368B (zh) | 一种用于治疗风湿寒热所致痹病的中药组合物及其制备方法 | |
CN101569739B (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN103041262B (zh) | 一种治疗慢性前列腺炎的中药灌肠剂及其制备方法 | |
CN102631538B (zh) | 一种治疗心脏病的中药 | |
CN102106980B (zh) | 一种治疗尿毒症的药物及制备方法 | |
CN104524106A (zh) | 一种治疗前列腺炎、前列腺肥大的中药制剂及其制备方法 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN102416121B (zh) | 一种药物组合物在制备治疗胃溃疡的药物中的用途 | |
CN106334171B (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
CN101112498B (zh) | 一种具有活血通络强筋壮骨的中药及其制备方法 | |
CN104547902A (zh) | 中药制剂用于制备治疗慢性肠炎、阑尾炎药物中的用途 | |
CN103860977B (zh) | 一种治疗皮炎的药物组合物 | |
CN116270949A (zh) | 一种降低高尿酸的中药组合物及其制备方法 | |
CN105214037A (zh) | 治疗消化性溃疡的固体分散胶囊剂 | |
CN104971271A (zh) | 一种治疗瘀湿化热型前列腺增生的药物及制备方法 | |
CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
CN103751467A (zh) | 一种治疗腰背筋膜炎的中药组合物及其制备方法 | |
CN100443105C (zh) | 一种治疗类风湿关节炎、骨质增生的药物及其制备方法 | |
CN1233383C (zh) | 一种治疗前列腺疾病的中药制剂及其制备方法 | |
CN107007697A (zh) | 一种治疗盆腔炎或前列腺炎的中药组合物及其制剂 | |
CN105169277A (zh) | 一种保肝利胆的栀子口服液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230623 |
|
RJ01 | Rejection of invention patent application after publication |